Chimeric fusion proteins - Pseudomonas exotoxin-based

Current Opinion in Investigational Drugs

Volumn 2, Issue 9, 2001, Pages 1282-1293

  Kreitman, R J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chronic lymphocytic leukemia; Fusion toxin; Fv; Hairy cell leukemia; Immunotoxin; Monoclonal antibody

Indexed keywords

ANTIBODY CONJUGATE; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; IMMUNOTOXIN; IMMUNOTOXIN LMB2; INTERLEUKIN 4 RECEPTOR; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B3; MONOCLONAL ANTIBODY B3(DSFV) PE38; MONOCLONAL ANTIBODY B3(FV) PE38; MONOCLONAL ANTIBODY BL22; MONOCLONAL ANTIBODY BR96(SCFV) PE40; MONOCLONAL ANTIBODY LMB 1; MONOCLONAL ANTIBODY LMB 7; MONOCLONAL ANTIBODY LMB 9; MONOCLONAL ANTIBODY RFB4(DSFV) PE38; MONOCLONAL ANTIBODY SGN 10; ONCOPROTEIN; PSEUDOMONAS EXOTOXIN; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BACTERIAL MUTATION; CANCER; CELL KILLING; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; ENDOTHELIUM INJURY; HUMAN; LIGAND BINDING; NONHUMAN; PLASMA HALF LIFE; REVIEW; SOLID TUMOR; VASCULAR DISEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTOXINS; LEUKEMIA; LEUKEMIA, B-CELL; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 0034821591     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (162)

1. Cancer statistics
2. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell
3. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells
4. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia
5. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B-cell leukemias
6. Accumulation of a recombinant immunotoxin in vivo: Less than 1000 molecules per cell is sufficient for complete responses
7. Preparation of a hybrid of fragment Fab' of antibody and fragment A of diphtheria toxin and its cytotoxicity
8. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is non-toxic
9. Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin
10. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody
11. The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides
12. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain
13. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors
14. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy
15. Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms
16. Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin
17. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma
18. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma
19. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma
20. Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies
21. Pharmacokinetic analysis of immunotoxin uptake in solid tumors: Role of plasma kinetics, capillary permeability, and binding
22. The spatial distribution of immunotoxins in solid tumors: Assessment by quantitative autoradiography
23. Getting plant toxins to fuse
24. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E coli
25. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 Angstrom resolution
26. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor
27. The α2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A
28. Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver
29. Characterization of a cellular protease that cleaves Pseudomonas exotoxin
30. 280 generates the enzymatically active fragment which translocates to the cytosol
31. Reduction of furin-nicked Pseudomonas exotoxin A: An unfolding story
32. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity
33. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor
34. Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes
35. The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion
36. Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin
37. The crystal structure of Pseudomonas aeruginosa exotoxin domain III with nicotinamide and AMP: Conformational differences with the intact exotoxin
38. Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: Implications for the activation process and for ADP ribosylation
39. 440 residue
40. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies
41. Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1
42. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein
43. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin
44. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: Relative importance of the two toxin disulfide bonds
45. EGF receptor and p185(erB-2)-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins
46. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL
47. Single-chain antigen-binding proteins
48. Protein engineering of antibody binding sites: Recovery of specific activity in an antidigoxin single-chain Fv analogue produced in Escherichia coli
49. A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin
50. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions
51. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin
52. Use of bacteriophage T7 polymerase to direct selective expression of cloned genes
53. A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies
54. Making fusion toxins to target leukemia and lymphoma
55. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells
56. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by Cynomolgus monkeys
57. Expression of epidermal growth factor receptor in human cultured cells and tissues: Relationship to cell lineage and stage of differentiation
58. Activity of a recombinant fusion protein between transforming growth factor type α and Pseudomonas toxin
59. Cytotoxic activities of a fusion protein comprised of TGF-α and Pseudomonas exotoxin
60. Rational design of a chimeric toxin: An intramolecular location for the insertion of transforming growth factor α within Pseudomonas exotoxin as a targeting ligand
61. Antitumor activity of a transforming growth factor α-Pseudomonas exotoxin fusion protein (TGF-α-PE40)
62. A recombinant form of Pseudomonas exotoxin A containing transforming growth factor α nears its carboxyl terminus for the treatment of bladder cancer
63. Transforming growth factor α-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts
64. Epidermal growth factor receptor binding is affected by structural determinants in the toxin domain of transforming growth factor-α-Pseudomonas exotoxin fusion proteins
65. Phase I clinical study of recombinant oncotoxin TP40 in superficial bladder cancer
66. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier
67. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display
68. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors
69. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors
70. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
71. Bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor
72. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin
73. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor
74. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas
75. Y damage human endothelial cells in an antibody-specific mode: Relevance to vascular leak syndrome
76. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice
77. BR96 sFv-PE40 immunotoxin: Non-clinical safety assessment
78. Influence of immunogenicity on the pharmacokinetics of BMS-191352, a Pseudomonas exotoxin immunoconjugate, in rats and dogs
79. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin
80. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein
81. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted IL-4 and Pseudomonas exotoxin
82. A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin
83. Site-specific conjugation to interleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity
84. Circularly permuted interleukin 4 retains proliferative and binding activity
85. A circularly permuted recombinant interleukin 4 toxin with increased activity
86. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma
87. Complete regression of established human glioblastoma tumor xenografts by interleukin-4 toxin therapy
88. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma
89. Intratumoral administration of a recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high grade glioma
90. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common γ-chain shared by receptors for interleukins 2, 4, 7, 9, and 15
91. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor
92. Interleukin-13 receptor as a specific molecular target for cytotoxin therapy of human renal cell carcinoma in a xenograft model
93. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncate form of Pseudomonas exotoxin A (PE38QQR)
94. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers
95. Isolation of anti-mesothelin antibodies from a phage display library
96. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity
97. Immunopathology of cutaneous T-cell lymphomas
98. 486IL-2 in advanced mycosis fungoides and the sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a phase II study
99. Interleukin-2 receptor β-chain (p70-75) expressed on leukemic cells from adult T-cell leukemia patients
100. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia
101. Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: Functional and structural characterization
102. Recombinant single-chain immunotoxins against T and B-cell leukemias
103. The immunophenotype of Reed-Sternberg cells. A study of 50 cases of Hodgkin's disease using fixed frozen tissues
104. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas: An immunohistologic study of 300 cases
105. The IL2/IL-2 receptor system: A current overview
106. Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli
107. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells
108. Only high-affinity receptors for interleukin 2 mediate internalization of ligand
109. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
110. The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia
111. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia
112. Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor
113. Hairy cell leukemia, a B-cell neoplasm which is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2)
114. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma
115. Targeting Pseudomonas exotoxin to hematologic malignancies
116. Pharmacokinetics of In-111- and I-125-labeled antiTac single-chain Fv recombinant immunotoxin
117. Responses in refractory hairy cell leukemia to a recombinant immunotoxin
118. Phase I trial of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies
119. Reduction of the nonspecific toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point
120. Inhibition of TNF-α produced by Kupffer cells protects against the non-specific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2
121. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines
122. Recombinant anti-CD25 immunotoxin RFT5(ScFv)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice
123. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study
124. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin
125. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome
126. Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model
127. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs
128. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity
129. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice
130. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity
131. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors
132. Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukemia
133. Treatment of hairy cell leukemia-variant (HCL-V) with cladribine
134. Hairy cell leukemia variant
135. Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine - A report of three cases
136. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment
137. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study
138. Long term results with 2′-deoxycoformycin in hairy cell leukemia
139. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
140. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: A long-term follow-up study
141. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia
142. Minimal residual disease, its detection and significance in hairy-cell leukemia
143. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine
144. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse
145. + B cell lymphoma
146. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a phase II study
147. Characterization of the interleukin 2 receptor β-chain using three distinct monoclonal antibodies
148. Phenotypic analysis of hairy cell leukemia: 'Variant' cases express the interleukin-2 receptor β-chain, but not the α-chain (CD25)
149. Mik-β1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the β-chain of the IL-2 receptor
150. Single-chain immunotoxins targeted to CD40 for the treatment of human B-lineage hematologic malignancies
151. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease
152. The t(2;5) in human lymphomas
153. CD30 expression is common in mediastinal large B-cell lymphoma
154. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA′) is a potent immunotoxin against a Hodgkin-derived cell line
155. Ki-4(scFv)-ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice
156. Isolation of new anti-CD30 scFvs from DNA immunized mice by phage display, and biologic activity of recombinant immunotoxins produced by fusion with truncated Pseudomonas exotoxin
157. Primate antibody response to immunotoxin: Serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin
158. Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins
159. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity
160. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice
161. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
162. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF